AOD-9604 (Advanced Obesity Drug-9604) is a synthetic peptide corresponding to the C-terminal fragment (amino acids 177-191) of human growth hormone (hGH). Developed by Monash University researchers, AOD-9604 was designed to capture the lipolytic (fat-metabolizing) properties of growth hormone while excluding its growth-promoting and diabetogenic effects. Although clinical development for obesity was discontinued after mixed Phase 2 results, ongoing research explores applications in cartilage repair and osteoarthritis.
Development History
AOD-9604 emerged from research by Professor Frank Ng and colleagues at Monash University in Melbourne, Australia, during the 1990s. The research team identified that the C-terminal region of human growth hormone (specifically the loop between amino acids 177-191, stabilized by a disulfide bond between residues 182 and 189) was responsible for the fat-metabolizing effects observed with full-length GH administration.
By synthesizing this fragment independently, researchers aimed to create a targeted anti-obesity agent without the adverse metabolic effects of exogenous GH—including insulin resistance, fluid retention, carpal tunnel syndrome, and potential tumor growth promotion. Early preclinical studies in obese Zucker rats and ob/ob mice showed that AOD-9604 stimulated lipolysis and inhibited lipogenesis without affecting IGF-1 levels or glucose tolerance.
Mechanism of Action
AOD-9604’s lipolytic mechanism differs from full-length growth hormone. The peptide does not bind the classical GH receptor (GHR) and does not activate JAK2-STAT5 signaling—the primary pathway through which GH promotes growth and IGF-1 production. Instead, AOD-9604 appears to interact with a distinct, as-yet-uncharacterized receptor or binding site on adipocyte membranes.
In adipocyte models, AOD-9604 stimulates lipolysis through activation of beta-3 adrenergic receptor signaling and increased hormone-sensitive lipase (HSL) activity. The peptide also inhibits lipogenesis by reducing expression of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) in fat tissue. Additionally, AOD-9604 has been shown to increase fat oxidation rates in isolated adipocyte preparations, suggesting enhanced mitochondrial fatty acid metabolism.
Importantly, AOD-9604 does not suppress appetite or alter food intake in animal studies. Its mechanism is purely metabolic—directly affecting fat cell metabolism rather than central appetite regulation. This distinguishes it from GLP-1 receptor agonists and other appetite-modifying approaches.
Clinical Trial History
Metabolic Pharmaceuticals (now Calzada Ltd) advanced AOD-9604 through clinical development. Phase 1 trials established safety and tolerability across dose ranges, with no significant adverse effects observed. Oral bioavailability was confirmed, an unusual property for a peptide, attributed to the fragment’s relative stability and small size.
Phase 2a trials showed encouraging trends in body weight reduction over 12 weeks. However, the pivotal Phase 2b trial, involving approximately 500 obese subjects over 24 weeks, did not achieve statistically significant weight loss versus placebo at the primary endpoint. While post-hoc analyses suggested potential benefits in certain subgroups, the overall result led to discontinuation of the obesity development program.
The clinical failure highlighted challenges in translating preclinical adipocyte-level effects to meaningful whole-body weight reduction. The effect size, while measurable at the cellular level, may have been insufficient to produce clinically significant weight loss in the context of human metabolic complexity and behavioral factors.
Cartilage Repair Research
Post-obesity development, AOD-9604 research shifted toward musculoskeletal applications. Studies demonstrated that the peptide promotes proteoglycan synthesis in chondrocytes—the specialized cells that produce and maintain cartilage matrix. In explant models of cartilage damage, AOD-9604 stimulated matrix repair and reduced degradation enzyme activity.
In vivo studies in osteoarthritis models showed that intra-articular AOD-9604 administration improved cartilage integrity, reduced joint space narrowing, and decreased inflammatory markers in synovial fluid. These findings led to AOD-9604 receiving Generally Recognized as Safe (GRAS) status for use in food products in 2023, and ongoing investigation of injectable formulations for joint applications.
Regulatory and Safety Considerations
AOD-9604 has a well-documented safety profile from its clinical development program. Across Phase 1 and Phase 2 trials, the peptide demonstrated minimal adverse effects. The absence of GH receptor activation means AOD-9604 does not carry the risks associated with exogenous growth hormone including acromegaly features, insulin resistance, or potential oncogenic effects. The World Anti-Doping Agency (WADA) classified AOD-9604 as a prohibited substance in 2023 under the category of peptide hormones.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 (Advanced Obesity Drug-9604) is a synthetic peptide fragment corresponding to amino acids 177-191 of human growth hormone. It was developed to isolate the fat-metabolizing activity of growth hormone without its growth-promoting or diabetogenic effects.
How does AOD-9604 differ from HGH?
AOD-9604 is a 16-amino-acid fragment of the 191-amino-acid HGH molecule. It retains the lipolytic activity attributed to the C-terminal region of HGH but does not bind the growth hormone receptor, so it does not stimulate IGF-1 production, promote tissue growth, or cause insulin resistance.
What happened in AOD-9604 clinical trials?
AOD-9604 progressed through Phase 2 clinical trials for obesity. While the peptide showed an acceptable safety profile, the primary weight loss endpoints did not reach statistical significance in Phase 2b trials. Development for obesity was discontinued, but research into cartilage repair continues.